Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards

Report: Six New Obesity Drugs Set to Launch by 2026

By GlobalData | November 13, 2018

Multiple big pharma companies are developing new anti-obesity drugs, including Novo Nordisk, Sanofi, and AstraZeneca, and six drugs are expected to launch by 2026, according to GlobalData, a data and analytics company. 

The current obesity market is rather sparse, comprising of only six FDA approved drugs on the U.S. market, two EMA approved drugs in the 5EU, only one PMDA approved drug in Japan, and two CFDA approved drugs in China. 

“Obesity has become an epidemic and it is recognized as one of the major health issues due to the high risk of developing chronic diseases, such as cardiovascular disease and type 2 diabetes,” Dr. Edit Kovalcsik, managing analyst at GlobalData, said. “It is now the most investigated indication within the metabolic disorders therapy area in the 8MM* by the number of trials.”

According to GlobalData’s report: “Obesity: Competitive Landscape to 2026” the obesity pipeline consists of 253 products across all indications and stages of clinical development across the 8MM.

Obesity Development Pipeline, by Phase, September 2018 (Source: GlobalData, Pharma Intelligence Center)

“The obesity market is about to expand, with the addition of five new-generation GLP-1RAs, including long-acting GLP-1RAs and dual GLP-1R and glucagon receptor (GCGR) agonists, and one first-in-class appetite regulating drug by 2026. This will cause significant changes in the obesity landscape particularly in the U.S. and the 5EU”, Kovalcsik said. “The obesity market will remain less impressive in Japan and China; only two anti-obesity drugs are likely to launch in Japan, while in China only one drug is likely to see the light by 2026, despite China having the second highest prevalence of obesity in the 8MM after the U.S.

“Novo Nordisk will remain a strong player in the obesity space for the next 10 years due to the company’s marketed GLP-1 analog, Saxenda, and a long-acting (once weekly) GLP-1 analog, semaglutide, which will be first to market among the new-generation GLP-1RAs in the obesity space in 2022,” Kovalcsik said. “However, the company’s leading obesity drug will face patent expiration and its new drug will compete with subsequently launching dual agonists designed to be more effective than those with a single target.”
___________________________________________________________

 * 8MM: U.S., France, Germany, Italy, Spain, U.K., Japan, China.

(Source: GlobalData)

Related Articles Read More >

Biden
Biden leaning on Defense Production Act to bolster COVID-19 vaccine supplies
Amazon offers to help Biden administration with vaccine distribution
Pfizer-BioNTech vaccine
U.S. government stockpile of COVID-19 vaccines already drained
Dr. David Kessler
Former FDA commissioner Kessler to help lead Biden’s COVID-19 response

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Pharmaceutical Processing World
  • Enews Signup
  • Contact Us
  • About Us
  • R&D World
  • DeviceTalks
  • Drug Discovery & Development
  • Drug Delivery Business News
  • MassDevice
  • Medical Design Sourcing

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards